T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$7.49B |
| 2 |
Micron Technology
MU
|
+$6.62B |
| 3 |
Lam Research
LRCX
|
+$3.45B |
| 4 |
Applied Materials
AMAT
|
+$3.03B |
| 5 |
Advanced Micro Devices
AMD
|
+$2.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1B |
| 2 |
Apple
AAPL
|
+$11.6B |
| 3 |
Amazon
AMZN
|
+$3.54B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.07B |
| 5 |
Keysight
KEYS
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.73% |
| 2 | Healthcare | 11.3% |
| 3 | Financials | 10.32% |
| 4 | Communication Services | 9.66% |
| 5 | Industrials | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LUCK
2901
Lucky Strike Entertainment
LUCK
$750M
| $257K | ﹤0.01% |
34,227
+18,078
| +112% | +$148K |
|
2902
Inseego
INSG
$70.6M
| $256K | ﹤0.01% |
24,716
+3,617
| +17% | +$48.5K |
|
2903
Vanda Pharmaceuticals
VNDA
$317M
| $256K | ﹤0.01% |
41,820
| – | – |
|
|
LOVE
2904
LoveSac
LOVE
$235M
| $255K | ﹤0.01% |
15,222
+417
| +3% | +$6.59K |
|
|
AVBH
2905
Avidbank Holdings
AVBH
$345M
| $255K | ﹤0.01% |
+7,714
| New | +$235K |
|
2906
Mistras Group
MG
$636M
| $254K | ﹤0.01% |
14,533
+4,209
| +41% | +$74.9K |
|
2907
Nuvectis Pharma
NVCT
$744M
| $254K | ﹤0.01% |
13,805
+1,757
| +15% | +$19.7K |
|
2908
Palisade Bio
PALI
$357M
| $254K | ﹤0.01% |
+121,152
| New | +$238K |
|
2909
Eledon Pharmaceuticals
ELDN
$229M
| $253K | ﹤0.01% |
63,984
+13,822
| +28% | +$50.3K |
|
2910
Latham Group
SWIM
$769M
| $253K | ﹤0.01% |
39,041
+6,869
| +21% | +$38.6K |
|
2911
OrthoPediatrics
KIDS
$566M
| $252K | ﹤0.01% |
13,173
+2,026
| +18% | +$35.2K |
|
2912
Comstock
LODE
$231M
| $252K | ﹤0.01% |
+60,572
| New | +$220K |
|
2913
Mastech Digital
MHH
$88.9M
| $252K | ﹤0.01% |
32,598
| – | – |
|
2914
Nathan's Famous
NATH
$402M
| $251K | ﹤0.01% |
2,460
+430
| +21% | +$43.5K |
|
2915
Verastem
VSTM
$719M
| $251K | ﹤0.01% |
65,565
+18,738
| +40% | +$90.7K |
|
|
ABX
2916
Abacus Global Management
ABX
$941M
| $250K | ﹤0.01% |
23,315
-8,990
| -28% | -$82.1K |
|
2917
PetMed Express
PETS
$37.1M
| $250K | ﹤0.01% |
129,933
+9,878
| +8% | +$21K |
|
2918
Arcturus Therapeutics
ARCT
$419M
| $248K | ﹤0.01% |
36,887
+7,094
| +24% | +$55.9K |
|
2919
Benitec Biopharma
BNTC
$428M
| $248K | ﹤0.01% |
+18,528
| New | +$220K |
|
2920
Cricut
CRCT
$1.14B
| $248K | ﹤0.01% |
56,403
| – | – |
|
2921
Fennec Pharmaceuticals
FENC
$409M
| $248K | ﹤0.01% |
23,029
+6,164
| +37% | +$50.3K |
|
2922
Century Therapeutics
IPSC
$368M
| $248K | ﹤0.01% |
+101,164
| New | +$231K |
|
2923
Tonix Pharmaceuticals
TNXP
$220M
| $248K | ﹤0.01% |
19,363
+5,547
| +40% | +$71.6K |
|
2924
Concrete Pumping Holdings
BBCP
$513M
| $247K | ﹤0.01% |
20,450
+761
| +4% | +$6.53K |
|
2925
Corbus Pharmaceuticals
CRBP
$171M
| $247K | ﹤0.01% |
26,271
+13,699
| +109% | +$130K |
|
Similar funds
T. Rowe Price Associates's Q2 2026 Portfolio in Review
As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
- T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
- T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
- T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
- T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
- T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.